Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 339 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Planned Chemotherapy Clear all
Completed Not applicable Interventional Results available

ACT for Life: a Brief Intervention for Maximizing Recovery After Suicidal Crises

NCT02751983
View directory record Official record
Conditions
Suicide, Psychiatric Rehabilitation
Interventions
ACT for Life, Treatment as usual
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

NCT02482441
View directory record Official record
Conditions
Advanced Relapsed Tumors, Refractory Solid Tumors
Interventions
OMP-131R10, FOLFIRI
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

NCT05057247
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
Interventions
Duvelisib, Docetaxel
Drug
Lead sponsor
Glenn J. Hanna
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 18, 2026, 5:37 AM EDT
Not listed Phase 1 Interventional

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

NCT03094884
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Pulsed Low Dose Radiation, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

NCT00417248
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Radiotherapy, Sorafenib
Drug · Procedure
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Galesburg, Illinois • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

NCT01717391
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
Interventions
fluorothymidine F 18
Drug
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

NCT00868608
View directory record Official record
Conditions
Lymphoma
Interventions
Inotuzumab Ozogamicin (CMC-544)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Loma Linda, California • Mission Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

NCT01240304
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation therapy, pancreaticoduodenectomy
Drug · Radiation · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

NCT04674306
View directory record Official record
Conditions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions
α-lactalbumin vaccine, Zymosan
Biological
Lead sponsor
George T. Budd
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

NCT06451159
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Biological · Drug
Lead sponsor
Bruce Cree
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07425054
View directory record Official record
Conditions
Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
Interventions
HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
Radiation · Drug
Lead sponsor
Jennifer Dorth
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tasquinimod, IRd chemotherapy
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 18, 2026, 5:37 AM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

NCT05108428
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

NCT00042367
View directory record Official record
Conditions
Brain Tumors
Interventions
Induction therapy (Regimen 1, Course 1, Cycle A1, Regimen 1, Course 1, Cycle A2 (Days 22 - 42), Cycle B, Regimen 1, Course 2, Intrathecal Mafosfamide, Regimen 1 Course 2, IT mafosfamide, Regimen 2, Course 1, Regimen 2, Course, 1, Cycle C1, Regimen 2, Course 2, radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 36 Months
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Durham, North Carolina • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
View directory record Official record
Conditions
Rectal Cancer
Interventions
CRLX101, Capecitabine, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 18, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 18, 2026, 5:37 AM EDT
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 18, 2026, 5:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Pressure First Medication Therapy Management

NCT04275934
View directory record Official record
Conditions
Hypertension, Blood Pressure, Cardiovascular Diseases
Interventions
Health Management; Blood Pressure
Behavioral
Lead sponsor
American Pharmacists Association Foundation
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 18, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

NCT06529809
View directory record Official record
Conditions
Locally Advanced Cervical Carcinoma
Interventions
Hypofractionated external beam radiation, Chemotherapy, Image-guided brachytherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 18, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

NCT05256745
View directory record Official record
Conditions
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Interventions
TTP488, ddAC/ddT, TC, TCHP, Chemotherapy regimen that includes ddAC
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 18, 2026, 5:37 AM EDT
Not listed Phase 2 Interventional

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

NCT03935256
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin and Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Marywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 18, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 18, 2026, 5:37 AM EDT